Clinical Trial Update: " Treating MS Patients With Lower Extremity Spasticity Using Dysport" [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating Dysport (abobotulinumtoxinA) for lower extremity spasticity in multiple sclerosis patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Dysport (abobotulinumtoxinA)

Snippet

Sponsor: Neurology Center of New England P.C. | Conditions: Multiple Sclerosis, Spasticity, Muscle | Phase 3 | Status: UNKNOWN